Form 4: Kiniksa Pharmaceuticals International, plc: Officer Tessari Eben Reports Stock Transactions

Chief Operating Officer Tessari Eben reports the acquisition and disposal of Kiniksa Pharmaceuticals International, plc shares on May 19, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On May 19, 2025, Eben Tessari, the Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, engaged in transactions involving Class A Ordinary Shares.
• Tessari acquired 7,000 shares at $3.8 and disposed of 12,000 shares at a weighted average price of $26.41.
• These transactions were executed under a 10b5-1 plan established on April 29, 2024.
• Following these transactions, Tessari directly owns 72,363 Class A Ordinary Shares.
• Tessari also exercised a share option for 7,000 shares at $3.8, which is fully vested and exercisable since June 28, 2027.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports stock transactions by an officer under a pre-arranged plan. There is no indication of positive or negative sentiment towards the company's prospects.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, suggesting a planned and orderly approach to stock transactions.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders, providing transparency into their trading activities. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may influence investor perception of the company's stock, although the pre-arranged nature of the 10b5-1 plan mitigates potential concerns about insider information.

Key Dates

Keywords

Kiniksa Pharmaceuticals, Form 4, Insider Trading, Eben Tessari, Stock Transactions, KNSA, 10b5-1 Plan